Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer.

J Immunother Cancer · 2021 · PMC8356172 · PMID 34376553

Europe PMC DOI

hedged sentence

0.0950

closest p · 1.9× alpha

0.0950

boldest claim

The sentences

did not reach statistical significancep=0.095so close (0.05 < p ≤ 0.1)

7 8 10 17 Positive PD-L1 expression was associated with longer PFS (PD-L1 positive vs negative: HR 0.48, 95% CI 0.30 to 0.77, p<0.001), but the difference did not reach statistical significance for OS (PD-L1 positive vs negative: HR 0.66, 95% CI 0.39 to 1.10, p=0.095).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.